BofA analyst Jason Zemansky lowered the firm’s price target on Kura Oncology (KURA) to $29 from $30 and keeps a Buy rating on the shares. Given the level of pre-announcements, upcoming Q4 earnings “may not have the same impact they’ve had in prior years,” the analyst tells investors in a preview for the firm’s biopharma coverage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology Tightens Governance with Amended Bylaws
- 3 ‘Strong Buy’ Biotech Stocks to Buy Today, 1/13/2026, According to Top Analysts
- Kura Oncology price target lowered to $20 from $25 at Leerink
- Kura Oncology reports inducement grants under Nasdaq listing rule
- Kura Oncology’s Promising Clinical Data and Strategic Partnerships Justify Buy Rating